60,071 Shares of Stoke Therapeutics, Inc. $STOK Bought by SYM FINANCIAL Corp

SYM FINANCIAL Corp bought a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 60,071 shares of the company’s stock, valued at approximately $1,562,000.

Several other hedge funds also recently made changes to their positions in STOK. Sterling Capital Management LLC grew its holdings in Stoke Therapeutics by 849.7% during the 3rd quarter. Sterling Capital Management LLC now owns 1,833 shares of the company’s stock valued at $48,000 after buying an additional 1,640 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Stoke Therapeutics by 4.6% in the third quarter. Assenagon Asset Management S.A. now owns 1,180,782 shares of the company’s stock valued at $30,700,000 after acquiring an additional 52,394 shares during the period. Tidal Investments LLC boosted its position in shares of Stoke Therapeutics by 16.1% in the second quarter. Tidal Investments LLC now owns 9,917 shares of the company’s stock valued at $324,000 after acquiring an additional 1,377 shares during the period. Squarepoint Ops LLC purchased a new position in Stoke Therapeutics during the second quarter valued at approximately $959,000. Finally, Corient Private Wealth LP purchased a new position in Stoke Therapeutics during the second quarter valued at approximately $1,009,000.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK opened at $26.13 on Wednesday. The stock’s 50-day simple moving average is $27.78 and its two-hundred day simple moving average is $30.97. Stoke Therapeutics, Inc. has a twelve month low of $20.32 and a twelve month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The business had revenue of $9.32 million during the quarter, compared to analysts’ expectations of $4.89 million. On average, equities analysts anticipate that Stoke Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In related news, Director Edward Kaye sold 12,567 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total value of $402,521.01. Following the transaction, the director directly owned 124,557 shares in the company, valued at approximately $3,989,560.71. This represents a 9.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 7,176 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $29.04, for a total transaction of $208,391.04. Following the completion of the sale, the insider directly owned 20,422 shares in the company, valued at $593,054.88. This represents a 26.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 34,594 shares of company stock valued at $1,069,305. 9.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Chardan Capital reaffirmed a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 4th. The Goldman Sachs Group reiterated a “buy” rating on shares of Stoke Therapeutics in a research note on Thursday, September 10th. Guggenheim reissued a “buy” rating and issued a $60.00 price target on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Wedbush boosted their price target on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. began coverage on shares of Stoke Therapeutics in a research report on Friday, August 21st. They set an “overweight” rating and a $40.00 price target for the company. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $44.25.

About Stoke Therapeutics

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.